Head-to-head evidence
adalimumab-ryvk (Simlandi) vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-ryvk (Simlandi)
Marketed by Alvotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
etanercept · Enbrel
Marketed by Amgen
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab-ryvk (Simlandi)
Marketed by Alvotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
etanercept · Enbrel
Marketed by Amgen
NCT00317499 · Phase 3 · completed
Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-ryvk (Simlandi)'s landscape · etanercept's landscape